Advertisement
Advertisement
RNXT
RenovoRx, Inc. Common Stock
1.40
USDSponsored
+0.14
+11.11%
Aug 14, 15:51 UTC -4
Closed
After-Market
1.41
+0.01
+0.36%
RNXT Earnings Reports
Positive Surprise Ratio
RNXT beat 13 of 20 last estimates.
65%
Next Report
Date of Next Report
Nov 11, 2026
Estimate for Q3 26 (Revenue/ EPS)
$827.73K
/-$0.07
Implied change from Q2 26 (Revenue/ EPS)
-9.04%
/+40.00%
Implied change from Q3 25 (Revenue/ EPS)
+211.18%
/-12.50%
RenovoRx, Inc. Common Stock earnings per share and revenue
On Aug 12, 2026, RNXT reported earnings of -0.05 USD per share (EPS) for Q2 26, beating the estimate of -0.07 USD, resulting in a 32.43% surprise. Revenue reached 910.00 thousand, compared to an expected 730.83 thousand, with a 24.52% difference. The market reacted with a +12.50% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 5 analysts forecast an EPS of -0.07 USD, with revenue projected to reach 827.73 thousand USD, implying an increase of 40.00% EPS, and decrease of -9.04% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
CorMedix Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
$0.24
Actual
$0.28
Surprise
+19.44%
Fate Therapeutics, Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.25
Surprise
+8.49%
Outlook Therapeutics, Inc. Common Stock
Report Date
Aug 14, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.09
Surprise
+5.46%
Caribou Biosciences, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.32
Actual
-$0.24
Surprise
+25.74%
ADC Therapeutics SA
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.21
Actual
-$0.11
Surprise
+49.12%
TuHURA Biosciences, Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.14
Surprise
+5.34%
Pelthos Therapeutics Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$3.10
Actual
-$6.62
Surprise
-112.99%
Lantern Pharma Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.28
Surprise
+27.76%
Elutia Inc. Class A Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.15
Actual
-$0.17
Surprise
-11.11%
Kyntra Bio, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$3.24
Actual
-$4.68
Surprise
-44.15%
FAQ
What were RenovoRx, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, RenovoRx, Inc. Common Stock reported EPS of -$0.05, beating estimates by 32.43%, and revenue of $910.00K, 24.52% above expectations.
How did the market react to RenovoRx, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 12.5%, changed from $1.12 before the earnings release to $1.26 the day after.
When is RenovoRx, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 11, 2026.
What are the forecasts for RenovoRx, Inc. Common Stock's next earnings report?
Based on 5
analysts, RenovoRx, Inc. Common Stock is expected to report EPS of -$0.07 and revenue of $827.73K for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement